Literature DB >> 23385635

Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.

Diego Cigna1, Claudia D'Anna, Carmela Zizzo, Daniele Francofonte, Iacopo Sorrentino, Paolo Colomba, Giuseppe Albeggiani, Alessandro Armini, Laura Bianchi, Luca Bini, Giovanni Duro.   

Abstract

Fabry disease (FD) is an X-linked progressive multisystem disease due to mutations in the gene encoding the lysosomal enzyme α-galactosidase A (α-GalA). The deficiency in α-GalA activity leads to an intra-lysosomal accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3), in various organs and systems. Enzyme replacement therapy is available and alternative therapeutic approaches are being explored. No diagnostic test, other than sequencing of the α-galactosidase A gene, is available, no biomarker has been proven useful to screen for and predict the disease, and underlying mechanisms are still elusive. The aim of this study is to identify FD specific biomarkers and to better understand the pathophysiological changes that occur over time in FD. We compared peripheral blood mononuclear cells (PBMC) from FD patients (n = 8) with control PBMC from healthy individuals (n = 6), by two-dimensional electrophoresis (2DE) and the detected differentially expressed proteins were then subjected to matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). In FD patients we identified, among the down-regulated proteins, Calnexin, Rho GDP-dissociation inhibitor 2, Rho GDP-dissociation inhibitor 1, Chloride intracellular channel protein 1; on the other hand γ-enolase, 14-3-3 protein theta, 14-3-3 protein zeta/delta, and galectin-1 were identified as up-regulated proteins. Calnexin and Rho GDP-dissociation inhibitor-1,2 are related to protein folding, signal transduction and cell proliferation. This is the first time that γ-enolase and galectin-1 are described to be up-regulated in Fabry patients. Levels of γ-enolase increase dramatically in cardiovascular accidents and cerebral trauma, whereas galectins are regulators of acute and chronic inflammation. These findings may improve our understanding of the molecular mechanisms underlying the pathology and provide new insight and knowledge for future studies in this field.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385635     DOI: 10.1039/c3mb25402j

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  11 in total

Review 1.  Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.

Authors:  Wenping Li; Stephanie M Cologna
Journal:  Mol Omics       Date:  2022-05-11

2.  Determination of variation parameters as a crucial step in designing TMT-based clinical proteomics experiments.

Authors:  Evelyne Maes; Dirk Valkenborg; Geert Baggerman; Hanny Willems; Bart Landuyt; Liliane Schoofs; Inge Mertens
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

3.  Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.

Authors:  Sun Hee Heo; Eungu Kang; Yoon-Myung Kim; Heounjeong Go; Kyung Yong Kim; Jae Yong Jung; Minji Kang; Gu-Hwan Kim; Jae-Min Kim; In-Hee Choi; Jin-Ho Choi; Sung-Chul Jung; Robert J Desnick; Han-Wook Yoo; Beom Hee Lee
Journal:  J Med Genet       Date:  2017-08-23       Impact factor: 6.318

4.  Signatures of Altered Gene Expression in Dorsal Root Ganglia of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Michaela Kress; Michiel Langeslag
Journal:  Front Mol Neurosci       Date:  2018-01-25       Impact factor: 5.639

Review 5.  Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now.

Authors:  Idalina Beirão; Ana Cabrita; Márcia Torres; Fernando Silva; Patrício Aguiar; Francisco Laranjeira; Ana Marta Gomes
Journal:  Diseases       Date:  2017-06-11

6.  Integrative Systems Biology Investigation of Fabry Disease.

Authors:  Marco Fernandes; Holger Husi
Journal:  Diseases       Date:  2016-11-15

7.  Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease.

Authors:  Diana Hernández-Romero; Jessica Sánchez-Quiñones; Juan Antonio Vílchez; José Miguel Rivera-Caravaca; Gonzalo de la Morena; Gregory Y H Lip; Vicente Climent; Francisco Marín
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

8.  Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy.

Authors:  Hui-Yung Song; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Chien-Ying Wang; Hsin-Bang Leu; Wen-Chung Yu; Yuh-Lih Chang; Shih-Hwa Chiou
Journal:  Cells       Date:  2019-04-08       Impact factor: 6.600

9.  Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.

Authors:  Yueh Chien; Shih-Jie Chou; Yuh-Lih Chang; Hsin-Bang Leu; Yi-Ping Yang; Ping-Hsing Tsai; Ying-Hsiu Lai; Kuan-Hsuan Chen; Wei-Chao Chang; Shih-Hsien Sung; Wen-Chung Yu
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

10.  A Proteomics-Based Analysis Reveals Predictive Biological Patterns in Fabry Disease.

Authors:  Abdellah Tebani; Wladimir Mauhin; Lenaig Abily-Donval; Céline Lesueur; Marc G Berger; Yann Nadjar; Juliette Berger; Oliver Benveniste; Foudil Lamari; Pascal Laforêt; Esther Noel; Stéphane Marret; Olivier Lidove; Soumeya Bekri
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.